ImmunityBio Faces Securities Class Action Lawsuit
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 3 days ago
0mins
Should l Buy IBRX?
Source: Globenewswire
- FDA Warning Letter: The FDA issued a warning letter to ImmunityBio, highlighting misleading claims made by Chairman Soon-Shiong regarding Anktiva's efficacy, which resulted in a more than 21% drop in share price on March 24, 2026, erasing nearly $2 billion in market capitalization and severely impacting investor confidence.
- Class Action Lawsuit: Hagens Berman has initiated a securities class action lawsuit against ImmunityBio on behalf of investors who purchased securities between January 19 and March 24, 2026, alleging violations of federal securities laws that could lead to further investor losses.
- Efficacy Claims Controversy: Soon-Shiong's assertion during a podcast that Anktiva could treat all cancers has been flagged by the FDA as misleading, lacking sufficient data to support such claims, which raises significant legal risks and public health concerns.
- Investor Rights Protection: Hagens Berman is urging investors who suffered substantial losses to report their losses and encouraging witnesses to assist in the investigation, reflecting a strong commitment to investor rights and demands for corporate transparency.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy IBRX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on IBRX
Wall Street analysts forecast IBRX stock price to rise
3 Analyst Rating
3 Buy
0 Hold
0 Sell
Strong Buy
Current: 6.980
Low
5.00
Averages
7.33
High
9.00
Current: 6.980
Low
5.00
Averages
7.33
High
9.00
About IBRX
Immunitybio, Inc. is a vertically integrated, clinical-stage biotechnology company developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Using its applied science and platforms to treat cancers, including the development of potential cancer vaccines, as well as developing immunotherapies and cell therapies to reduce or eliminate the need for standard high-dose chemotherapy. Its platforms and their associated product candidates are designed to attack cancer and infectious pathogens by activating both the innate immune system, including NK cells, dendritic cells, and macrophages, as well as the adaptive immune system comprising B and T cells, in an orchestrated manner. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins, vaccine vectors, and cell therapies. Its biologic commercial product candidate, Anktiva, is an IL-15 superagonist antibody-cytokine fusion protein.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
ImmunityBio Reports Strong Q1 2026 Revenue Growth and Milestones
- Significant Revenue Growth: ImmunityBio reported preliminary net product revenue of approximately $44.2 million for Q1 2026, reflecting a substantial 168% year-over-year increase, indicating continued adoption of ANKTIVA® among U.S. urologists and enhancing the company's market position.
- Annual Performance Breakthrough: The full-year 2025 net product revenue reached $113 million, a remarkable 700% increase over 2024, showcasing the company's strong performance in its commercialization efforts and setting the stage for future growth.
- Product Approval Expansion: ANKTIVA is now approved or authorized across five regulatory jurisdictions, covering approximately 34 countries, which enhances its competitive edge in global markets and lays a foundation for future sales growth.
- Clinical Trial Progress: The pivotal BCG-naïve NMIBC CIS trial (QUILT-2.005) is fully enrolled, with the Independent Data Monitoring Committee confirming adequate statistical power, and a supplemental BLA submission is on track for 2026, further supporting ANKTIVA's clinical applications.
See More
ImmunityBio Faces Securities Class Action Lawsuit
- FDA Warning Letter: The FDA issued a warning letter to ImmunityBio, highlighting misleading efficacy claims made by Chairman Soon-Shiong regarding Anktiva, which resulted in a more than 21% drop in share price on March 24, 2026, erasing nearly $2 billion in market capitalization and severely impacting investor confidence.
- Class Action Lawsuit Initiated: Hagens Berman has filed a securities class action lawsuit against ImmunityBio on behalf of investors who purchased securities between January 19 and March 24, 2026, alleging violations of federal securities laws that could lead to further losses for investors.
- Efficacy Claims Controversy: Soon-Shiong's assertion in a podcast that Anktiva could treat all cancers, not just bladder cancer, was strongly opposed by the FDA, which stated that promotional materials mislead the public and fail to provide complete information about Anktiva's FDA-approved indications, posing a potential public health risk.
- Investor Rights Protection: Hagens Berman is urging all investors who suffered significant losses during this period to submit their loss information and encouraging witnesses to assist in the investigation, reflecting a commitment to protecting investor rights while also indicating uncertainty about ImmunityBio's future prospects.
See More
ImmunityBio Faces Securities Fraud Class Action Lawsuit
- Lawsuit Announcement: Kessler Topaz Meltzer & Check, LLP has filed a securities fraud class action against ImmunityBio (IBRX) on behalf of investors who purchased shares between January 19 and March 24, 2026, highlighting significant investor concerns regarding the company's financial transparency.
- FDA Warning Impact: On March 24, 2026, ImmunityBio received a warning letter from the FDA due to misleading claims made by its Executive Chairman about Anktiva, resulting in a 21.12% drop in stock price, which raises investor apprehensions about the company's future prospects.
- False Statement Allegations: The lawsuit alleges that ImmunityBio made materially false statements regarding its business and operations, particularly concerning claims that Anktiva is a cancer vaccine, potentially leading to substantial financial losses for investors.
- Investor Action Recommendations: Investors are encouraged to apply for lead plaintiff status by May 26, 2026, to represent other investors in the class action, indicating a strong emphasis on corporate governance and legal compliance.
See More
Multiple Companies Face Class Action Lawsuits
- Atara Biotherapeutics Lawsuit: Atara is facing allegations for the period from May 20, 2024, to January 9, 2026, for failing to disclose manufacturing issues that jeopardized FDA approval for tabelecleucel, potentially leading to significant negative impacts on its financial condition.
- Coty Performance Issues: Coty Inc. is accused during the period from November 5, 2025, to February 4, 2026, of concealing underperformance in its Consumer Beauty segment and increased marketing investments that compressed margins, misleading investors about its business outlook.
- Super Micro Compliance Violations: Super Micro Computer is under scrutiny for the period from April 30, 2024, to March 19, 2026, for failing to disclose that a significant portion of its server sales to China violated U.S. export control laws, exposing the company to regulatory risks.
- ImmunityBio Capability Overstatement: ImmunityBio is facing allegations from January 19, 2026, to March 24, 2026, for overstating Anktiva's capabilities, resulting in misleading positive statements about the company's business prospects.
See More
ImmunityBio Securities Class Action Reminder
- Deadline for Filing: ClaimsFiler reminds investors that those who purchased ImmunityBio shares between January 19 and March 24, 2026, must file lead plaintiff applications by May 26, 2026, to participate in the securities class action lawsuit against the company.
- FDA Warning Letter: On March 24, 2026, a warning letter from the FDA to CEO Richard Adcock was made public, indicating that misleading advertisements for Anktiva violated the Federal Food, Drug, and Cosmetic Act, raising public health concerns.
- Significant Stock Drop: Following the release of the FDA warning letter, ImmunityBio's stock price plummeted by 21%, losing $1.98 per share to close at $7.42, highlighting investor concerns regarding the company's compliance and future outlook.
- Legal Consultation Services: ClaimsFiler offers a free shareholder information service, allowing investors to access information related to securities class actions and connect with Kahn Swick & Foti, LLC for legal options discussions.
See More
ImmunityBio Expects Q1 Net Revenue of $44.2 Million
- Significant Revenue Growth: ImmunityBio anticipates first-quarter net product revenue to reach approximately $44.2 million, representing a 168% year-on-year surge, which not only reflects strong market demand but also lays the groundwork for sustained future growth.
- Annual Performance Leap: The expected full-year net product revenue for 2025 is projected at $113 million, a staggering 700% increase from 2024, showcasing the company's success in product promotion and market penetration, thereby enhancing investor confidence.
- Expanded Product Approval: ANKTIVA, the interleukin-15-based immunotherapy, now holds approval or authorization in five regulatory jurisdictions, covering around 34 countries, indicating the company's growing influence in the global market.
- Stable Market Reaction: Although ImmunityBio's stock dipped 0.1% in Thursday's premarket, the company's strong performance expectations and product expansion plans may attract more investor attention in the future, boosting market confidence.
See More
ImmunityBio Reports Strong Q1 2026 Revenue Growth and Milestones
- Significant Revenue Growth: ImmunityBio reported preliminary net product revenue of approximately $44.2 million for Q1 2026, reflecting a substantial 168% year-over-year increase, indicating continued adoption of ANKTIVA® among U.S. urologists and enhancing the company's market position.
- Annual Performance Breakthrough: The full-year 2025 net product revenue reached $113 million, a remarkable 700% increase over 2024, showcasing the company's strong performance in its commercialization efforts and setting the stage for future growth.
- Product Approval Expansion: ANKTIVA is now approved or authorized across five regulatory jurisdictions, covering approximately 34 countries, which enhances its competitive edge in global markets and lays a foundation for future sales growth.
- Clinical Trial Progress: The pivotal BCG-naïve NMIBC CIS trial (QUILT-2.005) is fully enrolled, with the Independent Data Monitoring Committee confirming adequate statistical power, and a supplemental BLA submission is on track for 2026, further supporting ANKTIVA's clinical applications.
See More
ImmunityBio Faces Securities Class Action Lawsuit
- FDA Warning Letter: The FDA issued a warning letter to ImmunityBio, highlighting misleading efficacy claims made by Chairman Soon-Shiong regarding Anktiva, which resulted in a more than 21% drop in share price on March 24, 2026, erasing nearly $2 billion in market capitalization and severely impacting investor confidence.
- Class Action Lawsuit Initiated: Hagens Berman has filed a securities class action lawsuit against ImmunityBio on behalf of investors who purchased securities between January 19 and March 24, 2026, alleging violations of federal securities laws that could lead to further losses for investors.
- Efficacy Claims Controversy: Soon-Shiong's assertion in a podcast that Anktiva could treat all cancers, not just bladder cancer, was strongly opposed by the FDA, which stated that promotional materials mislead the public and fail to provide complete information about Anktiva's FDA-approved indications, posing a potential public health risk.
- Investor Rights Protection: Hagens Berman is urging all investors who suffered significant losses during this period to submit their loss information and encouraging witnesses to assist in the investigation, reflecting a commitment to protecting investor rights while also indicating uncertainty about ImmunityBio's future prospects.
See More
ImmunityBio Faces Securities Fraud Class Action Lawsuit
- Lawsuit Announcement: Kessler Topaz Meltzer & Check, LLP has filed a securities fraud class action against ImmunityBio (IBRX) on behalf of investors who purchased shares between January 19 and March 24, 2026, highlighting significant investor concerns regarding the company's financial transparency.
- FDA Warning Impact: On March 24, 2026, ImmunityBio received a warning letter from the FDA due to misleading claims made by its Executive Chairman about Anktiva, resulting in a 21.12% drop in stock price, which raises investor apprehensions about the company's future prospects.
- False Statement Allegations: The lawsuit alleges that ImmunityBio made materially false statements regarding its business and operations, particularly concerning claims that Anktiva is a cancer vaccine, potentially leading to substantial financial losses for investors.
- Investor Action Recommendations: Investors are encouraged to apply for lead plaintiff status by May 26, 2026, to represent other investors in the class action, indicating a strong emphasis on corporate governance and legal compliance.
See More
Multiple Companies Face Class Action Lawsuits
- Atara Biotherapeutics Lawsuit: Atara is facing allegations for the period from May 20, 2024, to January 9, 2026, for failing to disclose manufacturing issues that jeopardized FDA approval for tabelecleucel, potentially leading to significant negative impacts on its financial condition.
- Coty Performance Issues: Coty Inc. is accused during the period from November 5, 2025, to February 4, 2026, of concealing underperformance in its Consumer Beauty segment and increased marketing investments that compressed margins, misleading investors about its business outlook.
- Super Micro Compliance Violations: Super Micro Computer is under scrutiny for the period from April 30, 2024, to March 19, 2026, for failing to disclose that a significant portion of its server sales to China violated U.S. export control laws, exposing the company to regulatory risks.
- ImmunityBio Capability Overstatement: ImmunityBio is facing allegations from January 19, 2026, to March 24, 2026, for overstating Anktiva's capabilities, resulting in misleading positive statements about the company's business prospects.
See More
ImmunityBio Securities Class Action Reminder
- Deadline for Filing: ClaimsFiler reminds investors that those who purchased ImmunityBio shares between January 19 and March 24, 2026, must file lead plaintiff applications by May 26, 2026, to participate in the securities class action lawsuit against the company.
- FDA Warning Letter: On March 24, 2026, a warning letter from the FDA to CEO Richard Adcock was made public, indicating that misleading advertisements for Anktiva violated the Federal Food, Drug, and Cosmetic Act, raising public health concerns.
- Significant Stock Drop: Following the release of the FDA warning letter, ImmunityBio's stock price plummeted by 21%, losing $1.98 per share to close at $7.42, highlighting investor concerns regarding the company's compliance and future outlook.
- Legal Consultation Services: ClaimsFiler offers a free shareholder information service, allowing investors to access information related to securities class actions and connect with Kahn Swick & Foti, LLC for legal options discussions.
See More
ImmunityBio Expects Q1 Net Revenue of $44.2 Million
- Significant Revenue Growth: ImmunityBio anticipates first-quarter net product revenue to reach approximately $44.2 million, representing a 168% year-on-year surge, which not only reflects strong market demand but also lays the groundwork for sustained future growth.
- Annual Performance Leap: The expected full-year net product revenue for 2025 is projected at $113 million, a staggering 700% increase from 2024, showcasing the company's success in product promotion and market penetration, thereby enhancing investor confidence.
- Expanded Product Approval: ANKTIVA, the interleukin-15-based immunotherapy, now holds approval or authorization in five regulatory jurisdictions, covering around 34 countries, indicating the company's growing influence in the global market.
- Stable Market Reaction: Although ImmunityBio's stock dipped 0.1% in Thursday's premarket, the company's strong performance expectations and product expansion plans may attract more investor attention in the future, boosting market confidence.
See More
